secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001683168-24-008948
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health reports >65% DTC gross margin, advances VNS program with Feinstein Institute
--------------------------------------------------------------------------------

- ClearUP 2.0 launched; McKesson & Cardinal Health partnerships accelerating; customer reviews 4.4 stars; defect returns down.
- D2C gross margin over 65% (vs <28% in 2023); net operating loss reduced more than 30%.
- VNS pilot study with Feinstein Institute showed best-in-industry results; second study fully enrolled, data expected next year.
- Targeting $30B+ annual market opportunity in non-invasive VNS; 16 issued patents, 10 pending internationally.
- Plans disease-specific clinical trials in 2025, working to regain Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316824008948/0001683168-24-008948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316824008948/tivic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-008948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer